Welcome to our dedicated page for Belpointe Prep news (Ticker: OZ), a resource for investors and traders seeking the latest updates and insights on Belpointe Prep stock.
Belpointe PREP, LLC, which operates as Belpointe OZ, reports developments for a publicly traded qualified opportunity fund focused on real estate projects in qualified opportunity zones. Company news centers on leasing, construction, refinancing and capital strategy for multifamily and mixed-use assets, including Aster & Links in Sarasota and VIV in downtown St. Petersburg.
Updates also cover development pipeline activity, property-level financing, unitholder communications and Opportunity Zone program positioning. The company’s recurring announcements connect asset-level milestones with its Class A units listed on NYSE American under the symbol OZ.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Belpointe PREP, LLC (NYSE: OZ) announced the full repayment of all outstanding loans, including a $30 million related party loan. The Visco Loan of $5 million was repaid on December 6, 2022, while the Norpointe Loan of $30 million was repaid on December 13, 2022. CEO Brandon Lacoff noted that these transactions restored capital for further investments, with over $345 million raised for development projects worth approximately $1.3 billion. The company has filed a registration statement with the SEC for issuing up to $750 million in Class A units.
Belpointe PREP, LLC (NYSE American: OZ) has successfully acquired a 5.92-acre development site in Nashville, Tennessee for $16.2 million. This is the fifth investment in Nashville, where many companies are expanding, driving demand for rental housing. Partnering with CA South Development, the site will feature multiple mixed-use buildings. Belpointe OZ has raised over $345 million for its opportunity fund and has an extensive development pipeline totaling over $1.3 billion in project costs.